The New Notes and related guarantees are being offered only (1) in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and (2) outside the United States in offshore transactions to non-U.S. persons in compliance with Regulation S under the Securities Act. The New Notes and related guarantees have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This notice is issued pursuant to Rule 135c under the Securities Act, and does not constitute an offer to sell, or a solicitation of an offer to purchase, the New Notes.Forward-Looking Statements This communication contains forward-looking statements that may state GenOn or its management's intentions, beliefs, expectations or predictions for the future. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and typically can be identified by the use of words such as "will," "expect," "estimate," "anticipate," "forecast," "plan," "believe" and similar terms. Although GenOn believes that its expectations are reasonable, it can give no assurance that these expectations will prove to have been correct, and actual results may vary materially. Factors that could cause actual results to differ materially from those contemplated above include, among others, risks and uncertainties related to the capital markets generally and whether the Escrow Issuer will offer the New Notes, whether the Escrow Conditions are satisfied and the proposed Merger is consummated so that the offering is completed, the anticipated terms of the New Notes and the anticipated use of proceeds. The foregoing review of factors that could cause GenOn's actual results to differ materially from those contemplated in the forward-looking statements included herein should be considered in connection with information regarding risks and uncertainties that may affect GenOn's future results included in GenOn's filings with the SEC at www.sec.gov.